XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisition and Disposition (Tables)
3 Months Ended
Mar. 31, 2024
Acquisition and Disposition  
Schedule of purchase price allocation to the estimated fair value of the net assets acquired

(in thousands)

Amounts Recognized at Acquisition Date

Assets Acquired

Cash and cash equivalents

$

6,997

Investments in marketable securities

21,791

Other prepaids and other assets

5,260

In-process research and development

26,239

Out-licenses

13,530

Total assets

$

73,817

Liabilities Assumed

Accrued and other current liabilities

$

7,722

Deferred tax liability

1,499

Total liabilities

9,221

Total net assets acquired

$

64,596

Schedule of amount allocated to identifiable intangible assets

(in thousands)

Useful lives

    

Fair Value at Acquisition Date

In-process research and development - casdozokitug

n/a

$

25,899

In-process research and development - CHS-114

n/a

340

Out-license - GSK

15 years

2,506

Out-license - Novartis Institutes

15 years

11,024

Total identifiable intangible assets

$

39,769